OAM
ANIK icon

Oxford Asset Management’s Anika Therapeutics ANIK Stock Holding History

Oxford Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,620
Closed -$160K – 462
2025
Q4 		$160K Buy
+16,620
New +$159K 0.06% 409
2020
Q1 		– Sell
-30,219
Closed -$1.57M – 281
2019
Q4 		$1.57M Sell
30,219
-15,498
-34% -$900K 0.04% 571
2019
Q3 		$2.51M Sell
45,717
-71,355
-61% -$3.66M 0.06% 416
2019
Q2 		$4.75M Buy
117,072
+55,407
+90% +$2.02M 0.1% 249
2019
Q1 		$1.86M Sell
61,665
-21,172
-26% -$725K 0.04% 618
2018
Q4 		$2.78M Buy
82,837
+24,656
+42% +$890K 0.07% 321
2018
Q3 		$2.44M Buy
+58,181
New +$2.3M 0.05% 547
2018
Q2 		– Sell
-27,050
Closed -$1.34M – 1687
2018
Q1 		$1.34M Sell
27,050
-9,570
-26% -$541K 0.03% 785
2017
Q4 		$1.96M Buy
36,620
+4,048
+12% +$224K 0.04% 586
2017
Q3 		$1.9M Sell
32,572
-1,793
-5% -$93.7K 0.04% 645
2017
Q2 		$1.7M Sell
34,365
-25,651
-43% -$1.18M 0.03% 682
2017
Q1 		$2.61M Buy
60,016
+1,242
+2% +$59.3K 0.06% 342
2016
Q4 		$2.88M Sell
58,774
-29,035
-33% -$1.34M 0.1% 206
2016
Q3 		$4.2M Buy
87,809
+4,179
+5% +$206K 0.13% 181
2016
Q2 		$4.49M Sell
83,630
-21,415
-20% -$1.01M 0.15% 166
2016
Q1 		$4.7M Buy
105,045
+14,230
+16% +$577K 0.13% 173
2015
Q4 		$3.52M Buy
90,815
+49,771
+121% +$1.9M 0.08% 270
2015
Q3 		$1.31M Sell
41,044
-45
-0.1% -$1.57K 0.04% 357
2015
Q2 		$1.36M Sell
41,089
-19,584
-32% -$698K 0.04% 409
2015
Q1 		$2.5M Sell
60,673
-85,858
-59% -$3.47M 0.06% 319
2014
Q4 		$5.99M Buy
146,531
+63,945
+77% +$2.5M 0.13% 161
2014
Q3 		$3.1M Buy
+82,586
New +$3.57M 0.07% 283
2014
Q2 		– Sell
-108,953
Closed -$4.48M – 688
2014
Q1 		$4.48M Buy
108,953
+18,038
+20% +$670K 0.13% 239
2013
Q4 		$3.47M Sell
90,915
-31,865
-26% -$983K 0.09% 317
2013
Q3 		$2.94M Buy
122,780
+111,085
+950% +$2.49M 0.07% 357
2013
Q2 		$199K Buy
+11,695
New +$169K 0.01% 794

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Oxford Asset Management's ANIK Position: Q1 2026 in Review

Oxford Asset Management sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 16,620 shares — an estimated $160K sold.

Oxford Asset Management first reported a position in ANIK in Q2 2013 and held it in 26 quarters. The position peaked at $5.99M in Q4 2014. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Oxford Asset Management reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Oxford Asset Management sold 16,620 Anika Therapeutics shares in Q1 2026, an estimated $160K.
  • Oxford Asset Management first reported a position in Anika Therapeutics in Q2 2013 and held it in 26 quarters.
  • Oxford Asset Management's Anika Therapeutics position peaked at $5.99M in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.